Tip 2 Diyabet Mellituslu Hastalarda HbA1c Konsantrasyon Düzeylerine Göre Serum Adropin Düzeyinin Belirlenmesi

Abstract

Amaç : Adropin son yıllarda keşfedilmiş ve glukoz ve lipid metabolizması ile ilişkili olduğu bildirilmiştir. Amacımız Tip 2 Diabetes Mellitus tanısı almış hasta grupları ile kontrol grubu arasında kan glikozile hemoglobin (HbA1c) konsantrasyon değerlerine göre kan serum adropin düzeyleri arasındaki ilişkiyi belirlemektir. Metod: Fırat Üniversitesi Hastanesi Endokrinoloji kliniğinden gözlem amaçlı 60 Tip 2 DM, 20 prediyabet hastası alındı. Ayrıca karşılaştırma için 20 sağlıklı birey normal kontrol grubu olarak alındı. Toplam 60 DM hastası HbA1c düzeylerine göre %9'dan büyük 20, %7-9 arasında 20 ve %7'den küçük 20 hasta olmak üzere 3 eşit gruba ayrıldı. Rutin kan testlerine ek olarak ELISA yöntemi ile adropin düzeyleri ölçüldü. Bulgular: DM'li hastaların serum adropin düzeyleri kontrol grubuna göre daha düşüktü (4,12±1,23 ng/mlversus 4,84±1,41 ng/ml, p<0.05). HbA1c >%9 olan grubun adropin düzeyleri kontrol grubuna kıyasla daha düşüktü (3,23±1,14 ng/ml'ye karşı 4,84±1,41ng/ml, p < 0.001). Diyabetik hastalarda HbA1c ve adropin seviyeleri arasında negatif korelasyon tespit ettik (r=-0.377, p < 0.05). Sonuç: Bu çalışmada, adropin seviyelerinin artan HbA1c seviyeleri ile azaldığını bulduk. Kronik hipergliseminin veya zayıf kan şekeri regülasyonunun adropin seviyelerini düşürdüğü görülmektedir. Gelecekte, bu konuda daha fazla çalışmaya ihtiyaç vardır.

Keywords

• Tip 2 Diabetes mellitus
• Adropin
• HbA1c

Project Number

02.08.2013 tarihli Toplantı sayısı:02 Karar no:08

The Determination of serum Adropın level according to concentration levels of HbA1c in patients wıth Type 2 Diabetes Mellitus

Abstract

Purpose: Adropin is discovered in recent years and it has been reported to be associated with glucose and lipid metabolism . Our aim is to determine the relationship between blood serum adropin levels according to blood glycosylated hemoglobin (HbA1c) concentration values between the patient groups diagnosed with Type 2 Diabetes Mellitus and the control group. Methods: A total of 60 Type 2 DM, 20 prediabetes for observation were recruited from Endocrinology clinic of Fırat University Hospital. In addition, 20 healthy subjects were recruited for comparison as the normal control group. A total of 60 DM patients were divided into 3 equal groups according to HbA1c levels as 20 patients with HbA1c levels greater than 9 %, 20 between 7-9 %, 20 less than 7 %. In addition to routine blood tests, adropin levels were measured by ELISA method. Results: Patients with DM had lower serum adropin levels when compared with the controls (4,12±1,23 ng/mlversus 4,84±1,41 ng/ml, p<0.05). Adropin levels of the group with HbA1c > 9% was lower in comparison with control group (3,23±1,14 ng/ml versus 4,84±1,41ng/ml, p < 0.001). In diabetic patients we determined negative correlation between HbA1c and adropin levels (r=-0.377, p < 0.05). Conclusion: In this study, we found that adropin levels were reduced with increasing levels of HbA1c. It appears that chronic hyperglycemia or poor blood sugar regulation lowers adropin levels. In the future, on this subject further studies are needed.

Keywords

• Type 2 Diabetes mellitus
• Adropin
• HbA1c

Project Number

02.08.2013 tarihli Toplantı sayısı:02 Karar no:08

Ethical Statement

Çalışmanın etik kurulu Fırat Üniversitesi Etik kurulundan yukarıda belirtilen tarih ve sayı numarası ile alınmıştır.Yazarlar arasında bir çıkar çatışması yoktur.

Thanks

İlginize teşekkür ederim.Çalışmalarınızda başarılar dilerim

References

1. 1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Suppl 1): 20-S42.
2. 2. Ali II, D'Souza C, Singh J, Adeghate E. Adropin's Role in Energy Homeostasis and Metabolic Disorders. Int J Mol Sci. 2022; 23(15): 8318.
3. 3. Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research. Molecules. 2020; 25(3): 549.
4. 4. Kumar, K. G., Trevaskis, J. L., Lam, D. D., Sutton, G. M., Koza, R. A., et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell metabolism, 2008; 8(6): 468–81.
5. 5. Gunraj RE, Yang C, Liu L, Larochelle J, Candelario-Jalil E. Protective roles of adropin in neurological disease. Am J Physiol Cell Physiol. 2023; 324(3): 674-C678.
6. 6. Kwon OS, Andtbacka RHI, Hyngstrom JR, Richardson RS. Vasodilatory function in human skeletal muscle feed arteries with advancing age: the role of adropin J Physiol. 2019; 597(7): 1791-1804.
7. 7. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012; 97(10): 3783-3791.
8. 8. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C.Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 2013; 9: 1-8.

9. 9. Celik, A., Balin, M., Kobat, M. A., Erdem, K., Baydas, A., Bulut, M., et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovascular therapeutics, 2013; 31(3): 174–78.
10. 10. Lian W, Gu X, Qin Y, Zheng X.Elevated plasma levels of adropin in heart failure patients.Intern Med 2011; 50: 1523-27.
11. 11. Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr J. 2018; 65(7): 685-691.
12. 12. Celik, E., Yilmaz, E., Celik, O., Ulas, M., Turkcuoglu, I., Karaer, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. Journal of perinatal medicine, 2013; 41(4): 375–80.
13. 13. Aydin, S., Kuloglu, T., Aydin, S., Eren, M. N., Yilmaz, M., Kalayci, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Molecular and cellular biochemistry, 2013; 380(1-2): 73–81.
14. 14. Li S, Sun J, Hu W, et al. The association of serum and vitreous adropin concentrations with diabetic retinopathy. Ann Clin Biochem. 2019; 56(2): 253-258.
15. 15. Hu W, Chen L. Association of Serum Adropin Concentrations with Diabetic Nephropathy. Mediators Inflamm. 2016;2016:6038261.
16. 16. Beigi A, Shirzad N, Nikpour F, Nasli Esfahani E, Emamgholipour S, Bandarian F. Association between serum adropin levels and gestational diabetes mellitus; a case-control study. Gynecol Endocrinol. 2015; 31(12): 939-941.
17. 17. He Y, Li X, Li X, Cui W, Zhang S. Serum copeptin in women with gestational diabetes mellitus: A meta-analysis. Biomol Biomed. 2024;24(4):753-763.
18. 18. Dąbrowski FA, Jarmużek P, Gondek A, Cudnoch-Jędrzejewska A, Bomba-Opoń D, Wielgoś M. First and third trimester serum concentrations of adropin and copeptin in gestational diabetes mellitus and normal pregnancy. Ginekol Pol. 2016;87(9):629-634.